590 related articles for article (PubMed ID: 29127216)
1. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
2. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
3. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
4. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
5. Hutchinson-Gilford progeria syndrome.
Pollex RL; Hegele RA
Clin Genet; 2004 Nov; 66(5):375-81. PubMed ID: 15479179
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
7. Quantification of Farnesylated Progerin in Hutchinson-Gilford Progeria Patient Cells by Mass Spectrometry.
Camafeita E; Jorge I; Rivera-Torres J; Andrés V; Vázquez J
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233036
[TBL] [Abstract][Full Text] [Related]
8. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.
Koblan LW; Erdos MR; Wilson C; Cabral WA; Levy JM; Xiong ZM; Tavarez UL; Davison LM; Gete YG; Mao X; Newby GA; Doherty SP; Narisu N; Sheng Q; Krilow C; Lin CY; Gordon LB; Cao K; Collins FS; Brown JD; Liu DR
Nature; 2021 Jan; 589(7843):608-614. PubMed ID: 33408413
[TBL] [Abstract][Full Text] [Related]
9. Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes.
Moulson CL; Fong LG; Gardner JM; Farber EA; Go G; Passariello A; Grange DK; Young SG; Miner JH
Hum Mutat; 2007 Sep; 28(9):882-9. PubMed ID: 17469202
[TBL] [Abstract][Full Text] [Related]
10. A conserved splicing mechanism of the LMNA gene controls premature aging.
Lopez-Mejia IC; Vautrot V; De Toledo M; Behm-Ansmant I; Bourgeois CF; Navarro CL; Osorio FG; Freije JM; Stévenin J; De Sandre-Giovannoli A; Lopez-Otin C; Lévy N; Branlant C; Tazi J
Hum Mol Genet; 2011 Dec; 20(23):4540-55. PubMed ID: 21875900
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel RNA isoforms of LMNA.
DeBoy E; Puttaraju M; Jailwala P; Kasoji M; Cam M; Misteli T
Nucleus; 2017 Sep; 8(5):573-582. PubMed ID: 28857661
[TBL] [Abstract][Full Text] [Related]
13. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
14. Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects.
Strandgren C; Nasser HA; McKenna T; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
FASEB J; 2015 Aug; 29(8):3193-205. PubMed ID: 25877214
[TBL] [Abstract][Full Text] [Related]
15. Bone dysplasia in Hutchinson-Gilford progeria syndrome is associated with dysregulated differentiation and function of bone cell populations.
Cabral WA; Stephan C; Terajima M; Thaivalappil AA; Blanchard O; Tavarez UL; Narisu N; Yan T; Wincovitch SM; Taga Y; Yamauchi M; Kozloff KM; Erdos MR; Collins FS
Aging Cell; 2023 Sep; 22(9):e13903. PubMed ID: 37365004
[TBL] [Abstract][Full Text] [Related]
16. Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides.
Fong LG; Vickers TA; Farber EA; Choi C; Yun UJ; Hu Y; Yang SH; Coffinier C; Lee R; Yin L; Davies BS; Andres DA; Spielmann HP; Bennett CF; Young SG
Hum Mol Genet; 2009 Jul; 18(13):2462-71. PubMed ID: 19376814
[TBL] [Abstract][Full Text] [Related]
17. Alteration of splice site selection in the LMNA gene and inhibition of progerin production via AMPK activation.
Finley J
Med Hypotheses; 2014 Nov; 83(5):580-7. PubMed ID: 25216752
[TBL] [Abstract][Full Text] [Related]
18. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
[TBL] [Abstract][Full Text] [Related]
19. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome.
Scaffidi P; Misteli T
Nat Med; 2005 Apr; 11(4):440-5. PubMed ID: 15750600
[TBL] [Abstract][Full Text] [Related]
20. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
